stockrowVericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
Follow VCEL
Alert me
Vericel Corporation (VCEL) Shares outstanding
Vericel Corporation's shares outstanding at the end of fiscal 2025 was $52.2M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $53.0M. Over the past ten years it has ranged from $23.1M (fiscal 2016) to $52.2M (fiscal 2025) — the current reading is the highest in ten years. Vericel Corporation ranks 284th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $52.2M | 0.91% |
| FY2024 | $51.7M | 8.59% |
| FY2023 | $47.6M | 0.98% |
| FY2022 | $47.1M | 1.42% |
| FY2021 | $46.5M | (1.71%) |
| FY2020 | $47.3M | 7.02% |
| FY2019 | $44.2M | 9.79% |
| FY2018 | $40.2M | 20.65% |
| FY2017 | $33.4M | 44.44% |
| FY2016 | $23.1M | (2.81%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $53.0M | 1.24% |
| Jun 2026 | $52.3M | 3.03% |
| Mar 2026 | $50.8M | (2.64%) |
| Dec 2025 | $52.2M | 0.47% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ADMA ADMA Biologics Inc compare | $225.8M |
| BHVN Biohaven Ltd. compare | $151.0M |
| AUPH Aurinia Pharmaceuticals Inc compare | $135.2M |
| IMNM Immunome, Inc. compare | $113.3M |
| CLDX Celldex Therapeutics, Inc. compare | $77.8M |
| VERA Vera Therapeutics, Inc. compare | $71.8M |
| PHVS Pharvaris N.V. compare | $68.1M |
| VCEL Vericel Corporation | $53.0M |
| PVLA Palvella Therapeutics, Inc. compare | $14.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on VCEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement